Characteristics of nosocomial infection and its effects on the survival of chemotherapy patients with advanced non-small cell lung cancer
- Authors:
- Published online on: October 5, 2017 https://doi.org/10.3892/ol.2017.7144
- Pages: 7379-7383
-
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Abstract
Introduction
Lung cancer involves malignant tumors with highest morbidity and mortality rates thought the world. Further, rising levels of environmental pollution and the effects of smog on respiratory system could not be underestimated, especially in China (1,2). The incidence of lung cancer in the next few decades is expected to further rise (3). According to pathological classification, lung cancer could be divided into small cell lung cancer and non-small cell lung cancer (NSCLC). NSCLC accounts for more than 80% of cases. Also, more than 2/3 of NSCLC patients are diagnosed at advanced stage. So, the diagnostics are poor and the 5-year survival rate of this disease is extremely low (4).
Previous studies have confirmed that lung infection due to nosocomial infection is a common cause of death in patients with advanced lung cancer. The antibiotic-based treatment is the main treatment approach for the lung cancer patients with pulmonary infection (5). The effect of conventional antibiotic treatment is limited with the emergence of drug resistance. So, it would be of significant value to understand the distribution of drug resistance in patients with advanced lung cancer. This approach could further improve the treatment effect and extend their survival time (6). The present study summarized the characteristics of nosocomial infection in chemotherapy patients with advanced NSCLS. We also discussed the impact of nosocomial infection on the survival of patients.
Materials and methods
General information
Retrospective analysis was used to analyze the information of the 169 chemotherapy patients with NSCLC and nosocomial infection during hospitalization; 170 patients without nosocomial infection were also involved as a control group. All the patients were diagnosed as non-small cell lung cancer by fiberoptic bronchoscopy and biopsy. All the patients in observation group had nosocomial infection. There were 126 males and 44 females in the observation group. The ages ranged from 45 to 70 with a mean age of 61±1.0 years. The duration of disease ranged from 3 months to 2 years with a mean value of 5.1±0.2 months. Other clinical data of the patients in observation group included length of hospitalization, invasive operation, combination of two or more medical diseases, the use of prophylactic antibiotics, use of glucocorticoids and immunosuppressive agents. The patients with immune system disease and the patients who were combined with malignant tumors were excluded. The study obtained approval from the Ethics Committee of Binzhou City Central Hospital and all the participants signed the informed consent before enrollment.
Observation indicators
The distribution of pathogens in nosocomial infection in patients with advanced NSCLC was statistically analyzed. The distribution of major drug resistance of Gram-negative (G−) and Gram-positive (G+) were analyzed. The survival conditions of the patients were studied. The risk factors of nosocomial infection in patients with NSCLC were analyzed by univariate and multivariate logistic analyses.
Bacterial culture and species identification
According to the ‘National Clinical Laboratory Procedures’, routine testing methods were utilized. Drug susceptibility test was performed by paper diffusion method (K-B method). CLSI 2008–2010 operation procedures and result evaluation standards were used. Columbia blood plate, MH plates, identifying culture medium and drug sensitive slips were provided by the Oxoid (London, UK). The quality control strains viz. Staphylococcus aureus ATCC 25923, Pseudomonas aeruginosa ATCC 27853 and Escherichia coli ATCC 25922 were provided by provincial CDC clinical laboratory test center. The KB method is mainly used for the detection of ampicillin, cefotaxime, cefepime, ceftazidime, imipenem, clindamycin, vancomycin, erythromycin, roxithromycin, gentamicin and amikacin. The corresponding biological reagents were procured from Hangzhou Tianhe Microoragnism Reagents Co., Ltd. (Hangzhou, China). MH agar plates were stored at 4°C before use. Technicians with >5 years laboratory experience had performed all operations in strict accordance with the instructions.
Survey methods
The investigators were trained in a unified manner. The informed consent of the respondents was obtained. The investigators were familiar with the contents of the questionnaire and solutions to the frequently asked questions. Reliability coefficient was applied with values ranged from 0 to 1. The reliability of this study was 0.996. Two tests were performed using the same questionnaire on all subjects with an interval of 30 days to obtain the stability coefficient.
Statistical analysis
SPSS 21.0 software was utilized for statistical analyses (IBM, Armonk, NY, USA). The data were expressed as mean ± standard deviation. The t-test was used to compare the mean of the two groups. The χ2 test was used to compare the rates of the two groups. The univariate and multivariate logistic regression analysis was used for the analysis of correlation between the factors and the disease. P<0.05 was considered as statistically significant.
Results
The distribution of pathogens in nosocomial infection in chemotherapy patients with advanced NSCLC
G+ infection accounted for 45.6% cases. Staphylococcus aureus and coagulase-negative staphylococci were the most common species. The proportion of G− infection was 54.4%, of which Pseudomonas aeruginosa and Klebsiella pneumoniae were most common (Table I).
 | Table I.The distribution of pathogens in nosocomial infection in chemotherapy patients with advanced NSCLC. |
The main drug resistance distribution of G−
The most common drug-resistant antibiotics for Pseudomonas aeruginosa were sulfamethoxazole, ciprofloxacin and cefotaxime, while the most common drug-resistant antibiotics for Klebsiella pneumoniae infection were sulfonamides and gentamicin (Table II).
The main drug resistance distribution of G+
The most common drug-resistant antibiotics for Staphylococcus aureus were penicillin G, ampicillin and sulfamethoxazole, while the most common drug-resistant antibiotics for coagulase-negative staphylococci were penicillin G, ampicillin and sulfamethoxazole. Both of the G+ bacteria were sensitive to vancomycin and teicoplanin, and even more sensitive to imipenem or meropenem (Table III).
The characteristics of distribution of nosocomial infection sites
Nosocomial infections were most commonly found in respiratory system followed by the urinary system and digestive system, infections in skin, soft tissue and other parts (such as intracranial infection and intra-articular infection) (Table IV).
Comparison of the survival conditions between observation group and control group
The median survival time of the observation group was 5.1±0.3 months, while the median survival time of the control group was 8.5±0.6 months. Therefore, the median survival time of the observation group was significantly shorter than that of the control group (t=65.928, P<0.05) (Fig. 1). The median survival time of the observation group was 5.1±0.3 months, while the median survival time of the control group was 8.5±0.6 months. So, the median survival time of the observation group was significantly shorter than that of the control group (t=65.928, P<0.05).
Analyses of risk factors of nosocomial infection in patients with advanced with NSCLC
Invasive operation, combination of two or more diseases, the use of glucocorticoids and immunosuppressive agents in the course of treatment were observed commonly for NSCLC patients who were older than 60 years and have been hospitalized for 30 days or more (Table V).
Multivariate logistic analysis of nosocomial infection in patients with advanced NSCLC
Multivariate regression analysis showed that age over 60 years, invasive operation, combination of two or more diseases, the use of glucocorticoids and immunosuppressive agents were independent risk factors for nosocomial infection in patients with advanced NSCLC (Table VI).
Discussion
The concurrent chemo-radiotherapy is the main clinical treatment method for elderly patients with advanced lung cancer. However, cancer therapies result in reduced tolerance and immune capacity in patients (7,8). This compromised immune capacity resulted in high chances of nosocomial infection. In addition, lung cancer is usually combined with a variety of medical diseases. In elderly patients, the organ dysfunction and decreased immunity made them prone to various complications (9). The infection is extremely harmful for patients and could even lead to death. Previous studies have confirmed that nosocomial infection has become a serious threat to patients with advanced NSCLC leading to death (10). Therefore, the infection in these patients due to long-term chemo-radiotherapy is a difficult problem for the clinicians to solve. The aim of the present study was to analyze the characteristics of nosocomial infection and its impact on the survival of patients with advanced NSCLC during chemotherapy.
In the present study, pathogens of nosocomial infection have shown that G− infection is the main type of infection. Further, the mechanism of the emergency of drug resistance of Pseudomonas aeruginosa is complex. It could be explained by the ability of Pseudomonas aeruginosa to colonize with high variability (11). While the Klebsiella pneumoniae is a common extended-spectrum β-lactamases (ESBLs) strain, the gene of lactamases is the main cause of drug resistance. Klebsiella pneumoniae could produce lactamases for plasmid binding and transduction, which led to the emergency of drug resistance (12). This study found that the G− Klebsiella pneumoniae and Pseudomonas aeruginosa were highly sensitive to imipenem and meropenem. Infection may not be effectively controlled in G− infected patients with advanced NSCLC but it could lead to serious consequences. So imipenem or meropenem could be considered for early treatment of the above patients. G+ infection is sensitive to vancomycin and teicoplanin. Thus, imipenem or meropenem could be considered for the early treatment of G+ infected patients with advanced NSCLC.
The increased causes of respiratory infection may be due to the special anatomical structure of the respiratory system, the location of primary lesions and the use of ventilator treatment. Collectively this made the nosocomial infection pathogens penetration easier into the body through the respiratory tract. In addition, urinary tract infection may be related to the indwelling catheter in patients (13), long-term bed rest, prostatitis in elderly male patients (14,15) and reproductive system inflammation in elderly female patients (16,17). Gastrointestinal infections may be related to toxic side effects of chemotherapy, especially myelosuppression (18). The occurrence of nosocomial infections, regardless of the infection site, severity, affected the quality of life in the form of reduced body rehabilitation ability and less outdoor activities.
Our study on risk factors related to nosocomial infection in patients older than 60 years has shown that self-management ability, immunity capacity, bone marrow hematopoietic function and nutritional status were gradually decreased. Especially the combination of more than two kinds of medical diseases could significantly reduce the body anti-infective ability. So, toxic effects of radiotherapy and chemotherapy become more prominent causing increased incidence of nosocomial infection (19–21). Invasive operation itself is the source of iatrogenic infection. The implementation of persistent thoracic drainage on the patients with severe pleural effusion could lead to the loss of albumin leading to decline in immune capacity. Prolonged treatment with indwelling drainage and retrograde injection are other factors responsible for nosocomial infection. The use of glucocorticoids and immunosuppressive agents could significantly inhibit the body's immune capacity leading to nosocomial infection.
In conclusion, G− infection is the dominant type of nosocomial infection in patients with advanced NSCLC. G− infection, in respiratory system is sensitive to imipenem or meropenem and the infection seriously affect the survival of patients.
References
|
Takagi Y, Hosomi Y, Oshita F, Okamoto H, Seki N, Minato K, Aono H, Yamada K, Okuma Y, Hida N, et al: Feasibility study of docetaxel plus bevacizumab as first line therapy for elderly patients with advanced non-small-cell lung cancer: Thoracic Oncology Research Group (TORG) 1014. BMC Cancer. 15:740–750. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Kanda S, Horinouchi H, Fujiwara Y, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Kubota K, Tamura T and Ohe Y: Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy. Lung Cancer. 89:287–293. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Chen J, Chen J, Ding HY, Pan QS, Hong WD, Xu G, Yu FY and Wang YM: Use of an artificial neural network to construct a model of predicting deep fungal infection in lung cancer patients. Asian Pac J Cancer Prev. 16:5095–5099. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Huang BT, Lu JY, Lin PX, Chen JZ, Kuang Y and Chen CZ: Comparison of two RapidArc delivery strategies in stereotactic body radiotherapy of peripheral lung cancer with flattening filter free beams. PLoS One. 10:e01275012015. View Article : Google Scholar : PubMed/NCBI | |
|
Kubota K, Sakai H, Katakami N, Nishio M, Inoue A, Okamoto H, Isobe H, Kunitoh H, Takiguchi Y, Kobayashi K, et al: Tokyo Cooperative Oncology Group: A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial. Ann Oncol. 26:1401–1408. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Zhuang X, Herbert JM, Lodhia P, Bradford J, Turner AM, Newby PM, Thickett D, Naidu U, Blakey D, Barry S, et al: Identification of novel vascular targets in lung cancer. Br J Cancer. 112:485–494. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Morichika D, Sato-Hisamoto A, Hotta K, Takata K, Iwaki N, Uchida K, Minami D, Kubo T, Tanimoto M and Kiura K: Fatal Candida septic shock during systemic chemotherapy in lung cancer patient receiving corticosteroid replacement therapy for hypopituitarism: A case report. Jpn J Clin Oncol. 44:501–505. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Saito M, Saito W, Kanda A, Ohguro H and Ishida S: A case of paraneoplastic optic neuropathy and outer retinitis positive for autoantibodies against collapsin response mediator protein-5, recoverin, and α-enolase. BMC Ophthalmol. 14:5–10. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Gómez MT, Jiménez MF, Aranda JL, Rodríguez M, Novoa NM and Varela G: The risk of bilobectomy compared with lobectomy: A retrospective analysis of a series of matched cases and controls. Eur J Cardiothorac Surg. 46:72–75. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Andreas S, Rittmeyer A, Hinterthaner M and Huber RM: Smoking cessation in lung cancer-achievable and effective. Dtsch Arztebl Int. 110:719–724. 2013.PubMed/NCBI | |
|
Fernández Lorente A, Brooks Acosta S, Vinageras Neninger E, Alvarez Barroso MC, Brito Wilkinson B, Troche Concepción M, Martínez Pérez LB, González Viada CE, Diaz Crespo T and Casacó Parada AR: Effect of blockade of the EGF system on wound healing in patients vaccinated with CIMAvax® EGF. World J Surg Oncol. 11:2752013. View Article : Google Scholar : PubMed/NCBI | |
|
Goss GD, O'Callaghan C, Lorimer I, Tsao MS, Masters GA, Jett J, Edelman MJ, Lilenbaum R, Choy H, Khuri F, et al: Gefitinib versus placebo in completely resected non-small-cell lung cancer: Results of the NCIC CTG BR19 study. J Clin Oncol. 31:3320–3326. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Huang YH, Terabe M, Pendleton CD, Khursigara Stewart D, Bera TK, Pastan I and Berzofsky JA: Identification and enhancement of HLA-A2.1-restricted CTL epitopes in a new human cancerantigen-POTE. PLoS One. 8:643–665. 2013. | |
|
Ai Yang SS, Hsu K, Herbert C, Cheng Z, Hunt J, Lewis CR and Thomas PS: Mitochondrial DNA mutations in exhaled breath condensate of patients with lung cancer. Respir Med. 107:911–918. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Noro R, Yoshimura A, Yamamoto K, Miyanaga A, Mizutani H, Minegishi Y, Seike M, Kubota K, Kosaihira S, Hino M, et al: East Japan Chesters Group: Alternating chemotherapy with amrubicin plus cisplatin and weekly administration of irinotecan plus cisplatin for extensive-stage small cell lung cancer. Anticancer Res. 33:1117–1123. 2013.PubMed/NCBI | |
|
Kikuchi R, Isowa N, Tokuyasu H, Kawasaki Y, Onuma H, Miura H, Terada M, Takada T, Gejyo F, Suzuki E, et al: Three cases of resected pleomorphic carcinoma. Ann Thorac Cardiovasc Surg. 16:264–269. 2010.PubMed/NCBI | |
|
Tanaka J, Tajima S, Ito R, Shimaoka Y, Kuriyama H, Kagamu H, Terada M, Takada T, Gejyo F, Suzuki E, et al: Non-small cell lung carcinoma dying of acute respiratory failure due to aerogenous metastasis. Nihon Kokyuki Gakkai Zasshi. 47:652–657. 2009.(In Japanese). PubMed/NCBI | |
|
Van Arsdale SA: Chest mass mimicking an implanted port. Clin J Oncol Nurs. 12:673–674. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Wampler GL, Ahlgren JD, Lokich JJ, Gullo JJ and Phillips JA: Dichloromethotrexate, infusional cisplatin, and infusional 5-fluorouracil for locally advanced or metastatic non-small cell lung cancer. A MAOP study. Am J Clin Oncol. 14:442–445. 1991. View Article : Google Scholar : PubMed/NCBI | |
|
Belch AR, Urtasun RC, Bodnar D, Kinney B and Amy R: Use of hemibody irradiation as a non-cross-resistant agent in combination with systematic chemotherapy in small cell lung cancer. NCI Monogr. 11:271–274. 1988. | |
|
Evans WK, Feld R, Murray N, Pater J, Shelley W, Willan A, Osoba D, Levitt M, Coy P, Hodson I, et al: The use of VP-16 plus cisplatin during induction chemotherapy for small-cell lung cancer. Semin Oncol. 13 Suppl 3:10–16. 1986.PubMed/NCBI |
